1、 Product introduction
Chinese Name | English Name | Declaration Type | Department | Reportable Dosage Form | Declaration Progress | Strength | CAS |
富马酸替诺福韦二吡呋酯 | Tenofovir disoproxil fumarate | 5+4 | antiviral | Tablet / powder / capsule | Ready to declare | Tablet:150mg、200mg、250mg、300mg, Powder:40mg, Capsule :300mg | 202138-50-9 |
【Indication】
Treatment of HIV infection.
【Reportable Dosage Form &Strength】
Tablet: 150mg、200mg、250mg、300mg,
Powder:40mg,
Capsule :300mg
【Mechanism of Action】
Novel nucleotide reverse transcriptase inhibitors.
【Development Progress】
About to be accepted
2、 Clinical Advantages
Tenofovir is a first-line antiviral drug recommended by who AIDS treatment guidelines. In China, it is listed as the first-line drug of free AIDS antiviral treatment.
3、Domestic Declaration
Declaration Type | Reportable Dosage Form | Number of Declared Preparations | Number of Existing Preparation Enterprises |
5+4 | Tablet | Tablet :20 domestic powder :3 domestic capsule:3 domestic Compound:1 imported
| Tablet :1 imported |
![Brinzolamide 布林佐胺 CAS号:138890-62-7 Brinzolamide 布林佐胺 CAS号:138890-62-7]()
Guangzhou Tosun Pharmaceutical Ltd
FL 4-5,No.3, 2nd Kehui street, Science Park, Guangzhou High-tech Industrial Development Zone, Guangzhou, China. 510663
Tel: +86-20-66392521; Fax: +86-20-66392525